Anil Pareek

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3281707/publications.pdf

Version: 2024-02-01

1162889 839398 33 321 8 18 citations h-index g-index papers 33 33 33 446 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data. BMC Medicine, 2022, 20, 85.	2.3	9
2	Risk vs Benefits of Thiazides in Clinical Use: Need for a Holistic Approach. American Journal of Medicine, 2022, 135, e82-e83.	0.6	O
3	Hydroxychloroquine retinopathyâ€"less than meets the eye. Eye, 2021, 35, 2897-2897.	1.1	O
4	Cardiovascular safety of hydroxychloroquine: Brief appraisal of data. Journal of Diabetology, 2021, 12, 224.	0.1	0
5	Hydroxychloroquine and QT prolongation: reassuring data in approved indications. Rheumatology Advances in Practice, 2020, 4, rkaa044.	0.3	9
6	Interamerican Society of Cardiology (IASC) position statement: Chlorthalidone vs. thiazide-type diuretics. International Journal of Cardiology: Hypertension, 2020, 7, 100054.	2.2	1
7	2020 International Society of Hypertension Guidelines: preference of calcium channel blocker over thiazide-like diuretics lacks evidence. Journal of Hypertension, 2020, 38, 2335-2336.	0.3	4
8	Indian guidelines on hypertension-IV (2019): need to differentiate thiazide-like diuretics. Journal of Human Hypertension, 2020, 34, 841-842.	1.0	0
9	DAPA-HF study: Are the benefits uniform across non-diabetic subgroups. Indian Heart Journal, 2020, 72, 469-470.	0.2	O
10	SGLT2 inhibitor/GLP-1 receptor agonists as first step monotherapyâ€"evidence and implications. International Journal of Diabetes in Developing Countries, 2020, 40, 636-637.	0.3	1
11	Metformin use in T2D patients with reduced kidney function: reassuring, more evidence needed. International Journal of Diabetes in Developing Countries, 2020, 40, 638-638.	0.3	O
12	Optimising TRIUMPH with 6·25 mg chlorthalidone. The Lancet Global Health, 2020, 8, e175.	2.9	2
13	Compelling therapy of LVH: straight (and not-so-straight) inferences from evidence. Clinical Hypertension, 2019, 25, 25.	0.7	2
14	Is the CANVAS of canaglifozin wide?. International Journal of Diabetes in Developing Countries, 2018, 38, 353-354.	0.3	0
15	CANTOS: landmark study, modest benefits—more research needed. International Journal of Diabetes in Developing Countries, 2018, 38, 518-519.	0.3	O
16	Chlorthalidone, not hydrochlorothiazide, is the right diuretic for comparison. Clinical Hypertension, 2018, 24, 4.	0.7	5
17	Metabolic and cardiovascular benefits of hydroxychloroquine: exploration in a wider population at high CV risk. Annals of the Rheumatic Diseases, 2018, 77, e59-e59.	0.5	8
18	Hydroxychloroquine: Looking into the Future. Romanian Journal of Diabetes Nutrition and Metabolic Diseases, 2017, 24, 369-375.	0.3	5

#	Article	IF	CITATIONS
19	Congestive heart failure: more common as well as an important cardiovascular outcome. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 3, pvw046.	1.4	6
20	Drug approvals in India. Lancet Diabetes and Endocrinology, the, 2016, 4, 19-20.	5.5	2
21	Congestive heart failure: More common as well as an important cardiovascular outcome. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, , .	1.4	2
22	Re: Pareek A, Chandurkar N, Thomas N, <i>et al.</i> Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. Curr Med Res Opin 2014;30:1257-66. Current Medical Research and Opinion, 2015, 31, 1087-1092.	0.9	1
23	Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia. Current Medical Research and Opinion, 2015, 31, 2105-2117.	0.9	28
24	Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. Current Medical Research and Opinion, 2014, 30, 1257-1266.	0.9	76
25	Comparison of gastrointestinal safety and tolerability of aceclofenac with diclofenac: a multicenter, randomized, double-blind study in patients with knee osteoarthritis. Current Medical Research and Opinion, 2013, 29, 849-859.	0.9	27
26	Comparative evaluation of efficacy and safety of artesunate-lumefantrinevs. artemether-lumefantrine fixed-dose combination in the treatment of uncomplicatedPlasmodium falciparummalaria. Tropical Medicine and International Health, 2013, 18, 578-587.	1.0	8
27	Zaltoprofen, a noninferior alternative to diclofenac for the treatment of primary knee osteoarthritis – a comparative evaluation of efficacy and safety in a 4-week, multicentric, randomized, double-blind, double-dummy trial. Expert Opinion on Pharmacotherapy, 2011, 12, 1007-1015.	0.9	5
28	Efficacy and safety of aceclofenac and drotaverine fixed-dose combination in the treatment of primary dysmenorrhoea: a double-blind, double-dummy, randomized comparative study with aceclofenac. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2010, 152, 86-90.	0.5	15
29	Effect of atorvastatin and hydroxychloroquine combination on blood glucose in alloxan-induced diabetic rats. Indian Journal of Pharmacology, 2009, 41, 125.	0.4	12
30	Aceclofenac–tizanidine in the treatment of acute low back pain: a double-blind, double-dummy, randomized, multicentric, comparative study against aceclofenac alone. European Spine Journal, 2009, 18, 1836-1842.	1.0	55
31	A randomized, multicentric, comparative evaluation of aceclofenac–paracetamol combination with aceclofenac alone in Indian patients with osteoarthritis flare-up. Expert Opinion on Pharmacotherapy, 2009, 10, 727-735.	0.9	11
32	A randomized, comparative study evaluating the efficacy and tolerability of losartan-low dose chlorthalidone (6.25 mg) combination with losartan-hydrochlorothiazide (12.5 mg) combination in Indian patients with mild-to-moderate essential hypertension. Expert Opinion on Pharmacotherapy, 2009, 10, 1529-1536.	0.9	20
33	Comparative evaluation of efficacy and safety of cefotaxime-sulbactam with amoxicillin-clavulanic acid in children with lower respiratory tract infections. Expert Opinion on Pharmacotherapy, 2008, 9, 2751-2757.	0.9	7